

Please try another search
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing, and commercializing products and therapies for people with rare diseases. Its lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. Its pipeline features development programs for rare diseases associated with growth hormone deficiencies. Its subsidiaries include NewLink International, BlueLink Pharmaceuticals, Inc, BioProtection Systems Corporation and Lumos Pharma Sub, Inc.
Name | Age | Since | Title |
---|---|---|---|
An van Es-Johansson | 61 | 2021 | Independent Director |
Thomas A. Raffin | 74 | 1999 | Lead Independent Director |
Lota S. Zoth | 61 | 2012 | Independent Director |
Chad Allen Johnson | 42 | 2018 | Independent Director |
Mark A. Bach | 64 | 2021 | Scientific Advisory Board Member |
Kevin M. Lalande | 49 | 2014 | Independent Director |
Reiko Horikawa | - | - | Member of Scientific Advisory Board |
Joseph S. McCracken | 68 | 2020 | Independent Director |
George Werther | - | - | Member of Scientific Advisory Board |
Peter Clayton | - | - | Member of Scientific Advisory Board |
Ron Rosenfeld | - | - | Member of Scientific Advisory Board |
Richard J. Hawkins | 72 | 2011 | CEO & Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review